Abstract
Hepatoid adenocarcinoma of the lung (HAL) is a rare and aggressive subtype of lung cancer. The prognosis for patients with HAL is generally poor and currently, there are only limited treatment options. Here, we present a case of a 47-year-old male diagnosed with locally advanced-stage HAL who achieved a remarkably long disease-free survival after receiving neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery. This case highlights the potential of immunochemotherapy plus surgery in improving outcomes for patients with HAL.
Keywords:
Hepatoid adenocarcinoma of the lung; camrelizumab; immunotherapeutics; surgery; survival.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / therapy
-
Adenocarcinoma of Lung* / drug therapy
-
Adenocarcinoma of Lung* / pathology
-
Adenocarcinoma of Lung* / therapy
-
Antibodies, Monoclonal, Humanized* / administration & dosage
-
Antibodies, Monoclonal, Humanized* / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chemotherapy, Adjuvant / methods
-
Disease-Free Survival
-
Humans
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / therapy
-
Male
-
Middle Aged
-
Neoadjuvant Therapy* / methods
-
Treatment Outcome
Substances
-
camrelizumab
-
Antibodies, Monoclonal, Humanized
Grants and funding
This research was supported by the National Key Research and Development Program of China [Grant number: 2022YFC2407303], Major Science and Technology Projects of Zhejiang Province [Grant number: 2020C03058], and Research Center for Lung Tumor Diagnosis and Treatment of Zhejiang Province [Grant number: JBZX-202007].